



Attorney's Docket No.: 17456-007008

1H 1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : George P. Vlasuk et al. Art Unit : 1653
Serial No. : 09/498,556 Examiner : Rita Mitra
Filed : February 4, 2000
Title : NEMATODE-EXTRACTED SERINE PROTEASE INHIBITORS AND
ANTICOAGULANT PROTEIN

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated June 16, 2004 (copy enclosed), applicants submit the following remarks.

06 1050
2202 45
2201 86

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit July 16, 2004

Signature Carrie A. Amonte

Typed or Printed Name of Person Signing Certificate Carrie A. Amonte

08/15/2004 17:03:06 00000000 061/00 00000000
01 00:00:00 43.00 DA
02 00:00:00 36.00 DA

REMARKS


In the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequences dated June 16, 2004, applicants were asked to amend the Sequence Listing to include Formula III, which is recited in the specification and in claims 270 and 271. It is applicants' position that Formula III is a formula and not a specific amino acid sequence of the type that falls under the requirements of 37 C.F.R. §1.821-1.825. That Formula III is a formula and not a specific amino acid sequence of the type that falls under the requirements of 37 C.F.R. §1.821-1.825 is evident from the claims. For example, claim 270 recites that A2 is "an amino acid sequence" and that A4 is "an amino acid sequence having a net anionic charge". Thus, neither A2 nor A3 can be represented by an amino acid in accordance with WIPO Standard ST.25 (1998).

In view of the forgoing, Applicant respectfully request that the Examiner withdraw the requirement that Formula III be placed in the Sequence Listing and withdraw the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequences dated June 16, 2004. Applicants believe that the claims are in condition for allowance. Please apply any charges to Deposit Account No. 06-1050.

Respectfully submitted,

Date: _____

15 July 2004


Anita L. Melklejohn, Ph.D.
Reg. No. 35,283

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906